XNAS
PTPI
Market cap1mUSD
Jun 06, Last price
0.03USD
1D
4.70%
1Q
-67.85%
IPO
-99.03%
Name
Petros Pharmaceuticals Inc
Chart & Performance
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
242.34%
Rev. gr., 5y
218.58%
Revenues
5.11b
+87,699.77%
Net income
-14m
L+75.41%
CFO
-2.60b
L+34,031.53%
Profile
Petros Pharmaceuticals, Inc., a pharmaceutical company, focuses on men's health therapeutics. The company engages in the commercialization and development of Stendra, an PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). It also develops and commercializes H100, a patented topical formulation candidate for the treatment of acute Peyronie's disease. The company markets its line of ED products in the form of vacuum erection device products. Petros Pharmaceuticals, Inc. is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | |||||||
Revenues | 5,112,043 87,699.77% | 5,822 -2.83% | 5,992 -23.29% | ||||
Cost of revenue | 3,827,750 | 4,040 | 4,030 | ||||
Unusual Expense (Income) | |||||||
NOPBT | 1,284,293 | 1,782 | 1,962 | ||||
NOPBT Margin | 25.12% | 30.61% | 32.75% | ||||
Operating Taxes | 12,478,369 | 7,000 | |||||
Tax Rate | 971.61% | 356.71% | |||||
NOPAT | (11,194,076) | 1,782 | (5,038) | ||||
Net income | (14,319) 75.41% | (8,163) -69.81% | (27,038) 189.01% | ||||
Dividends | (1,292,916) | ||||||
Dividend yield | 4,089.62% | ||||||
Proceeds from repurchase of equity | 13,001 | 3 | |||||
BB yield | -423.74% | -0.06% | |||||
| Debt | |||||||
Debt current | 7,311 | 1,282 | 1,090 | ||||
Long-term debt | 213 | 7,258 | 8,913 | ||||
Deferred revenue | |||||||
Other long-term liabilities | 75,148 | 3,550 | |||||
Net debt | (3,702,447) | (4,798) | 577 | ||||
| Cash flow | |||||||
Cash from operating activities | (2,603,051) | (7,627) | (12,797) | ||||
CAPEX | (1) | ||||||
Cash from investing activities | (24,587) | ||||||
Cash from financing activities | (6,999,366) | 11,537 | (1,624) | ||||
FCF | (467,882) | 1,925 | (6,803) | ||||
| Balance | |||||||
Cash | 3,709,971 | 13,337 | 9,426 | ||||
Long term investments | |||||||
Excess cash | 3,454,369 | 13,046 | 9,127 | ||||
Stockholders' equity | (102,573,060) | (98,480) | (90,726) | ||||
Invested Capital | 95,188,016 | 122,787 | 117,169 | ||||
ROIC | 1.49% | ||||||
ROCE | 7.33% | 7.42% | |||||
| EV | |||||||
Common stock shares outstanding | 80,260 | 2,176 | 2,070 | ||||
Price | 0.39 -72.06% | 1.41 -39.48% | 2.33 -30.03% | ||||
Market cap | 31,615 930.40% | 3,068 -36.39% | 4,824 33.02% | ||||
EV | 6,964,478 | (1,321) | 5,400 | ||||
EBITDA | 4,228,041 | 5,197 | 7,561 | ||||
EV/EBITDA | 1.65 | 0.71 | |||||
Interest | 561 | 536 | 596 | ||||
Interest/NOPBT | 0.04% | 30.09% | 30.37% | ||||